Evidence map›Paper›PMID 41465368›Full record

ReviewInternational journal of molecular sciences2025

Nanomedicine for Cancer and Autoimmune Immunotherapy.

Ashi Ramavat, Priya Antil, Soniya Kaushik, Baby Kataria, Ramendra Pati Pandey

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Advances in nanotechnology applied to natural products.Beilstein journal of nanotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ashi RamavatDepartment of Biotechnology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India.ORCID 0009-0008-5712-3868
Priya AntilDepartment of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology (DCRUST), Sonepat 131001, Haryana, India.
Soniya KaushikDepartment of Biotechnology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India.ORCID 0009-0002-2154-7470
Baby KatariaDepartment of Microbiology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India.
Ramendra Pati PandeyDepartment of Biotechnology, SRM University, Delhi-NCR, Sonepat 131029, Haryana, India.ORCID 0000-0002-5196-6468

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomedicine has now become a transformative platform that enhances the precision and efficacy of immunotherapy approaches and allows customizations like never before when it comes to cancer, as well as autoimmune conditions. Using platforms based on nanoscale, researchers have been able to manipulate immune responses operating across spatial and temporal scales to address key limitations of conventional immunotherapy associated with working with immune response such as immune evasion, systemic toxicity, and poor pharmacokinetics. Sophisticated nanoparticles (such as stimuli-sensitive ones, exosome-mimetic vesicle nanoparticles, and nanoparticles with CRISPR) allow directed immunomodulators, antigens, and gene-editing systems to reach one or more particular immune compartments. The innovations allow reprogramming of immune cells, immune tolerance rejuvenation, and expansion of antitumor immunity without significant off-target effects. Finding applications in integrating the artificial intelligence as well as multi-omics techniques, the process leads to personalization of the nano-immunotherapies based on patient-specific immuno-signatures. The chapter discusses the mechanistic rationale, therapeutic advancement, and the translational opportunities of nanotechnology-based immunotherapies that define them as part of a foundation of future generations of clinical approaches to precision immune modulation in oncology and autoimmune diseases.

Indexed as

Autoimmune DiseasesImmunotherapyNanomedicineNeoplasmsAnimalsHumansNanoparticlesCAR-T cell enhancementcytokine regulationexosome-mimetic nanoplatformstumor microenvironment (TME)

Identifiers

PMID41465368
PMCPMC12732791

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.